109 related articles for article (PubMed ID: 34801511)
1. Identification of a peptide that disrupts hADA3-E6 interaction with implications in HPV induced cancer therapy.
Chand V; Kapoor A; Kundu S; Nag A
Life Sci; 2022 Jan; 288():120157. PubMed ID: 34801511
[TBL] [Abstract][Full Text] [Related]
2. High-risk HPV16E6 stimulates hADA3 degradation by enhancing its SUMOylation.
Chand V; John R; Jaiswal N; Johar SS; Nag A
Carcinogenesis; 2014 Aug; 35(8):1830-9. PubMed ID: 24795430
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3.
Kumar A; Zhao Y; Meng G; Zeng M; Srinivasan S; Delmolino LM; Gao Q; Dimri G; Weber GF; Wazer DE; Band H; Band V
Mol Cell Biol; 2002 Aug; 22(16):5801-12. PubMed ID: 12138191
[TBL] [Abstract][Full Text] [Related]
4. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator.
Zeng M; Kumar A; Meng G; Gao Q; Dimri G; Wazer D; Band H; Band V
J Biol Chem; 2002 Nov; 277(47):45611-8. PubMed ID: 12235159
[TBL] [Abstract][Full Text] [Related]
5. HPV16 E6-induced and E6AP-dependent inhibition of the transcriptional coactivator hADA3 in human cervical carcinoma cells.
Hu Y; Ye F; Lu W; Hong D; Wan X; Xie X
Cancer Invest; 2009 Mar; 27(3):298-306. PubMed ID: 19194825
[TBL] [Abstract][Full Text] [Related]
6. Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation.
Meng G; Zhao Y; Nag A; Zeng M; Dimri G; Gao Q; Wazer DE; Kumar R; Band H; Band V
J Biol Chem; 2004 Dec; 279(52):54230-40. PubMed ID: 15496419
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of small molecule human papillomavirus E6 inhibitors.
Malecka KA; Fera D; Schultz DC; Hodawadekar S; Reichman M; Donover PS; Murphy ME; Marmorstein R
ACS Chem Biol; 2014 Jul; 9(7):1603-12. PubMed ID: 24854633
[TBL] [Abstract][Full Text] [Related]
8. Tale of a multifaceted co-activator, hADA3: from embryogenesis to cancer and beyond.
Chand V; Nandi D; Mangla AG; Sharma P; Nag A
Open Biol; 2016 Sep; 6(9):. PubMed ID: 27605378
[TBL] [Abstract][Full Text] [Related]
9. hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells.
Shamanin VA; Sekaric P; Androphy EJ
J Virol; 2008 Apr; 82(8):3912-20. PubMed ID: 18256148
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness.
Leung TH; Tang HW; Siu MK; Chan DW; Chan KK; Cheung AN; Ngan HY
J Pathol; 2018 Feb; 244(2):151-163. PubMed ID: 28944962
[TBL] [Abstract][Full Text] [Related]
11. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE
J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422
[TBL] [Abstract][Full Text] [Related]
12. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
13. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
Drews CM; Case S; Vande Pol SB
PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
[TBL] [Abstract][Full Text] [Related]
14. Effects of the antifungal agent ciclopirox in HPV-positive cancer cells: Repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis.
Braun JA; Herrmann AL; Blase JI; Frensemeier K; Bulkescher J; Scheffner M; Galy B; Hoppe-Seyler K; Hoppe-Seyler F
Int J Cancer; 2020 Jan; 146(2):461-474. PubMed ID: 31603527
[TBL] [Abstract][Full Text] [Related]
15. PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.
Saidu NEB; Filić V; Thomas M; Sarabia-Vega V; Đukić A; Miljković F; Banks L; Tomaić V
J Virol; 2019 Dec; 94(1):. PubMed ID: 31597772
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance.
Bourguignon LYW; Earle C; Shiina M
Matrix Biol; 2019 May; 78-79():180-200. PubMed ID: 30077625
[TBL] [Abstract][Full Text] [Related]
17. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
18. C/EBPbeta activity and HPV-16 E6/E7 mRNA expression are not altered by imiquimod (ALDARA) in human cervical cancer cells in vitro.
Belcastro M; Miller MR; Flynn DC; Soisson AP
Gynecol Oncol; 2004 Feb; 92(2):660-8. PubMed ID: 14766263
[TBL] [Abstract][Full Text] [Related]
19. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.
Celegato M; Messa L; Goracci L; Mercorelli B; Bertagnin C; Spyrakis F; Suarez I; Cousido-Siah A; Travé G; Banks L; Cruciani G; Palù G; Loregian A
Cancer Lett; 2020 Feb; 470():115-125. PubMed ID: 31693922
[TBL] [Abstract][Full Text] [Related]
20. High-risk human papillomavirus infection and E6 protein expression in lesions of the uterine cervix.
Pillai MR; Lakshmi S; Sreekala S; Devi TG; Jayaprakash PG; Rajalakshmi TN; Devi CG; Nair MK; Nair MB
Pathobiology; 1998; 66(5):240-6. PubMed ID: 9732239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
